research Activity of Sorafenib Against Desmoid Tumor/Deep Fibromatosis
Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.
Search
for
Sort by
Research
30 / 120 results 
research Molecular Targeted Therapies for Cancer: Sorafenib Monotherapy and Its Combination with Other Therapies
Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
research Sorafenib-Induced Eruption Resembling Pityriasis Rubra Pilaris
A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
research Sorafenib Combined with Hepatectomy in Patients with Intermediate-Stage and Advanced Hepatocellular Carcinoma
Sorafenib after liver surgery may increase survival for some liver cancer patients.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
research Patient-Level Adverse Event Patterns in a Single-Institution Study of the Multi-Kinase Inhibitor Sorafenib
Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
research Sorafenib Stimulates Human Skin Type Mast Cell Degranulation and Maturation
Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.
research Delayed Onset Perforating Folliculitis Associated with Sorafenib
Sorafenib can cause delayed skin problems, so patients need careful monitoring.
research Case of Alopecia Induced by Sorafenib, Possible Mechanism Similar to Alopecia Areata
Sorafenib may cause hair loss in a way similar to alopecia areata.
research Tyrosine Kinase Inhibitors: A Review on Pharmacology, Metabolism, and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research Cutaneous Reactions to Chemotherapeutic Drugs and Targeted Therapy for Cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Skin Toxicity of Anti-Cancer Therapy
Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
research Unusual Progression of Renal Cell Carcinoma with Carcinomatosis Peritoneii and Krukenberg Tumor and Alopecia with Sunitinib Therapy in a Young Female
A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
research Adverse Hair Reactions to New Targeted Therapies for Cancer
New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
research Cutaneous and Mucosal Side Effects of New Anticancer Drugs: EGF-R Inhibitors, Tyrosine Kinase Inhibitors, and Mitotic Spindle Stabilizers
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
research Molecular Targeted Agents and Biologic Therapies for Non-Small Cell Lung Cancer
New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
research Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Unexpected Autocrine Role of Vascular Endothelial Growth Factor in Squamous Cell Carcinoma
VEGF helps squamous cell carcinoma grow in ways beyond just blood vessel formation.
research Cutaneous Adverse Effects of Targeted Therapies
Targeted cancer therapies often cause serious skin problems that need careful management.
research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
research Supportive Oncodermatology: Addressing Dermatologic Adverse Events Associated with Oncologic Therapies
Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.
research Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Understanding phenotypic plasticity is crucial for developing effective cancer therapies.
research The PDGF/PDGFR Pathway as a Drug Target
The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Targeting the Wnt Pathways for Therapies
Blocking the Wnt pathway could lead to new treatments for cancer and tissue repair but requires careful development to avoid side effects.
research Pathogenesis of Hand-Foot Syndrome Induced by PEG-Modified Liposomal Doxorubicin
PEGL-DOX causes Hand-Foot Syndrome due to skin reactions from prolonged circulation and ROS generation.
research Anagen Effluvium: A Review of Rapid Hair Loss During Growth Phase and Loose Anagen Hair Syndrome
Hair usually grows back 1-3 months after treatment for anagen effluvium, and children with Loose Anagen Hair Syndrome often improve by adolescence.
research Hair Disorders in Patients with Cancer
Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.